Galectin Therapeutics (GALT) Operating Expenses (2010 - 2026)

Galectin Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 48.37% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $16.3 million, a 60.02% decrease from a year earlier, with the FY2025 full-year figure at $20.1 million, down 52.67% from the prior year.
• Operating Expenses grew to $4.1 million in Q1 2026 per GALT's latest filing, from $3.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $12.4 million in Q4 2024 and bottomed at $3.4 million in Q4 2025.
• The 5-year median for Operating Expenses is $9.2 million (2023), against an average of $8.4 million.
• Across the five-year window, Operating Expenses surged 57.27% in 2022 and slumped 72.92% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $10.6 million in 2022, then slipped by 10.08% to $9.6 million in 2023, then grew by 29.99% to $12.4 million in 2024, then slumped by 72.92% to $3.4 million in 2025, then climbed by 21.16% to $4.1 million in 2026.
• Per Business Quant, the three latest GALT Operating Expenses figures stand at $4.1 million (Q1 2026), $3.4 million (Q4 2025), and $4.2 million (Q3 2025).